Arcus Biosciences
- Country
- ๐บ๐ธUnited States
- Ownership
- Public
- Established
- 2015-01-01
- Employees
- 577
- Market Cap
- -
- Website
- http://www.arcusbio.com
- Introduction
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
- Conditions
- Gastrointestinal Tract Malignancies
- Interventions
- First Posted Date
- 2022-04-15
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT05329766
- Locations
- ๐บ๐ธ
Mayo Clinic - Arizona, Phoenix, Arizona, United States
๐บ๐ธUSC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
๐บ๐ธRonald Reagan UCLA Medical Center, Santa Monica, California, United States
A Study to Evaluate Pharmacokinetics (PK) of Etrumadenant Tablet and Capsule Formulations in Healthy Adult Participants
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT05277012
- Locations
- ๐บ๐ธ
Investigational Site, Lincoln, Nebraska, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Itraconazole on the Pharmacokinetic Profile of Etrumadenant in Healthy Adult Participants
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05154136
- Locations
- ๐บ๐ธ
Celerion, Lincoln, Nebraska, United States
Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile With Oral AB521 in Healthy Volunteers
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2021-11-11
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05117554
- Locations
- ๐ณ๐ฑ
Investigational Site, Groningen, Netherlands
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies
- Conditions
- MelanomaAdvanced Solid TumorEsophageal CancerNon Small Cell Lung Cancer (NSCLC)Multiple MyelomaCervical CancerLymphoma, Non-HodgkinDiffuse Large B Cell Lymphoma (DLBCL)Gastroesophageal Junction AdenocarcinomaGastric Cancer
- Interventions
- First Posted Date
- 2021-02-26
- Last Posted Date
- 2025-06-29
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 94
- Registration Number
- NCT04772989
- Locations
- ๐บ๐ธ
UCLA Department of Medicine - Hematology/Oncology, Los Angeles, California, United States
๐บ๐ธMayo Clinic Jacksonville - PPDS, Jacksonville, Florida, United States
๐บ๐ธGoshen Health System, Goshen, Indiana, United States
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerNonsquamous Non Small Cell Lung CancerLung Cancer
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 169
- Registration Number
- NCT04736173
- Locations
- ๐บ๐ธ
Hope and Healing Cancer Service, Hinsdale, Illinois, United States
๐ฌ๐ทGeneral hospital of Athens, chest diseases Sotiria, Athens, Greece
๐ฌ๐ทUniversity General Hospital "Attikon", Chaidari, Greece
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: m-FOLFOX-6 regimen
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 227
- Registration Number
- NCT04660812
- Locations
- ๐ช๐ธ
Corporacio Sanitaria Parc Tauli, Sabadell, Spain
๐บ๐ธArizona Clinical Research Center Inc, Tucson, Arizona, United States
๐บ๐ธCity of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study to Investigate the Pharmacokinetic Profile of Oral AB680 in Healthy Volunteers
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04575311
- Locations
- ๐ฆ๐บ
Nucleus Network, Melbourne, Victoria, Australia
Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Androgen-Resistant Prostatic NeoplasmsCastration Resistant Prostatic NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Cancer, Castration-Resistant
- Interventions
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 173
- Registration Number
- NCT04381832
- Locations
- ๐บ๐ธ
The Oncology Institute of Hope & Innovation, Cerritos, California, United States
๐บ๐ธThe University of California, Los Angeles, Encino, California, United States
๐บ๐ธThe University of California, Irvine Medical Center, Orange, California, United States
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer
- Conditions
- Squamous Non Small Cell Lung CancerNon Small Cell Lung CancerLung CancerNonsquamous Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2025-06-27
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 151
- Registration Number
- NCT04262856
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธInnovative Clinical Research Institute (ICRI), Whittier, California, United States
๐บ๐ธFlorida Cancer Specialists, Gainesville, Florida, United States